Viking Therapeutics Inc. saw its stock price surge 6.0% to $34.30 in Tuesday afternoon trading, as investors placed bets on the upcoming late-stage clinical data for the company's lead obesity treatment, VK2735. The rally occurred without any new company announcements and despite a broader market downturn, highlighting the high expectations surrounding the drug's potential.
Market Context and Price Action
The Nasdaq-listed shares traded as high as $35.90 after opening at $31.76, with trading volume exceeding 5.1 million shares. This gain stood out on a weak trading day, as the Nasdaq Composite fell 1.7% and the S&P 500 declined, driven by a tech-led selloff. Reuters reported that chip stocks were leading the decline in U.S. equities.
VK2735: A Key Catalyst
VK2735 is a dual GLP-1 and GIP receptor agonist, targeting gut-hormone pathways that regulate appetite and blood sugar. The drug is currently in Phase 3 testing, a critical stage typically used to support regulatory filings. The company has guided investors to expect data from a maintenance-dosing study in the third quarter of 2026. Viking previously announced that its injectable Phase 3 trials, VANQUISH-1 and VANQUISH-2, are fully enrolled, while oral tablet trials are expected to begin in the fourth quarter.
Competitive Landscape
The obesity drug market is fiercely competitive, dominated by Novo Nordisk and Eli Lilly. Analysts project the sector could generate approximately $100 billion in annual sales over the next decade. Viking, unlike its larger rivals, has no approved obesity product, making the success of VK2735 crucial for its future. Eli Lilly is expected to launch its weight-loss pill in Europe and Britain in the second half of 2026 or early 2027, targeting the out-of-pocket telehealth market.
Financial Position and Risks
As of March 31, Viking held $603 million in cash, cash equivalents, and short-term investments, down from $706 million at year-end. The company has not generated revenue since inception and has cautioned that earlier trial results may not predict later-stage outcomes. Delays, safety issues, or weaker efficacy could slow approval, increase costs, and pressure the stock price.
Investor Sentiment
The stock's rally reflects investor optimism for a late-stage win in a crowded market. However, with no room for a messy readout, the upcoming data release will be a pivotal test for Viking. For now, the trade is centered on the optionality of VK2735's potential to compete in the obesity space.
